A Sham-Controlled Study to Evaluate the Safety and Efficacy of a Smart, Self-Adjusting, Surgery-Free, Wearable Bladder Neuromodulation System for Overactive Bladder

NATerminatedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

April 14, 2022

Primary Completion Date

July 1, 2023

Study Completion Date

July 1, 2023

Conditions
Overactive BladderUrinary Urge IncontinenceUrge Incontinence
Interventions
DEVICE

Avation System

Subjects will perform therapy with active Avation System three (3) times a week for thirty (30) minutes each time over a 12-week period. At the end of the twelve (12) weeks of therapy, eligible Subjects from the Active Arm will be offered the opportunity to participate in the additional twenty one (21) month Open-Label Phase.

DEVICE

Sham Avation System

Subjects will perform therapy with sham Avation System three (3) times a week for thirty (30) minutes each time over a 12-week period. At the end of the twelve (12) weeks of therapy, all Subjects from the Sham Arm will be offered the opportunity to crossover and participate in the additional twenty one (21) month Open-Label Phase.

Trial Locations (6)

60453

Women's Health Institute, Oak Lawn

70121

Ochsner Medical Center, New Orleans

71106

Regional Urology, Shreveport

77598

Tranquil Medical Rsearch, Webster

78229

Flourish Research, San Antonio

85745

Eclipse Clinical Research, Tucson

Sponsors
All Listed Sponsors
lead

Avation Medical, Inc.

INDUSTRY

NCT05381116 - A Sham-Controlled Study to Evaluate the Safety and Efficacy of a Smart, Self-Adjusting, Surgery-Free, Wearable Bladder Neuromodulation System for Overactive Bladder | Biotech Hunter | Biotech Hunter